Adverse events associated with nafamostat mesylate and favipiravir treatment in COVID-19 patients

被引：12
|
作者：
Hifumi, Toru [1 ]
Isokawa, Shutaro [1 ]
Otani, Norio [1 ]
Ishimatsu, Shinichi [1 ]
机构：
[1] St Lukes Int Hosp, Dept Emergency & Crit Care Med, Chuo Ku, 9-1 Akashi Cho, Tokyo 1048560, Japan
来源：
CRITICAL CARE | 2020年 / 24卷 / 01期
关键词：
COVID-19; Adverse events; Nafamostat mesylate; Favipiravir;
D O I：
10.1186/s13054-020-03227-4
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Pharmacokinetic characterization of favipiravir in patients with COVID-19
    Gulhan, Rezzan
    Eryuksel, Emel
    Oglu, Medine Gulcebi Idriz
    Culpan, Yekta
    Toplu, Aylin
    Kocakaya, Derya
    Tigen, Elif
    Sengel, Buket Erturk
    Sili, Uluhan
    Yildizeli, Sehnaz Olgun
    Balcan, Mehmet Baran
    Elci, Abdullah
    Bulut, Cenk
    Karaalp, Atila
    Yananli, Hasan Raci
    Guner, Abdullah Emre
    Hatipoglu, Mustafa
    Karakurt, Sait
    Korten, Volkan
    Ratnaraj, Neville
    Patsalos, Philip
    Ay, Pinar
    Onat, Filiz
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2022, 88 (07) : 3516 - 3522
  • [32] Population pharmacokinetics of favipiravir in patients with COVID-19
    Irie, Kei
    Nakagawa, Atsushi
    Fujita, Hirotoshi
    Tamura, Ryo
    Eto, Masaaki
    Ikesue, Hiroaki
    Muroi, Nobuyuki
    Fukushima, Shoji
    Tomii, Keisuke
    Hashida, Tohru
    CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2021, 10 (10): : 1161 - 1170
  • [33] Hematological Malignancy Patients, COVID-19, and Favipiravir
    Mungmunpuntipantip, Rujittika
    Wiwanitkit, Viroj
    TURKISH JOURNAL OF HEMATOLOGY, 2021, 38 (04) : 331 - 332
  • [34] Favipiravir and the Need for Early Ambulatory Treatment of COVID-19
    Korman, Tony M.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2021, 65 (03)
  • [35] Ivermectin associated adverse events in the treatment and prevention of COVID-19 reported to the FACT pharmacovigilance project
    Farah, Rita
    Kazzi, Ziad
    Brent, Jeffrey
    Burkhart, Keith
    Wax, Paul
    Aldy, Kim
    CLINICAL TOXICOLOGY, 2022, 60 (08) : 942 - 946
  • [36] The COVID-19 pandemic's impacts on adverse events associated with care
    Morgand, Claire
    Cabarrot, Philippe
    Coniel, Marie
    Prunet, Caroline
    Gloanec, Marie
    Morin, Sandrine
    May-Michelangeli, Laetitia
    Grenier, Catherine
    SANTE PUBLIQUE, 2021, 33 (06): : 959 - 970
  • [37] Favipiravir for the treatment of patients with COVID-19: a systematic review and meta-analysis
    Toshie Manabe
    Dan Kambayashi
    Hiroyasu Akatsu
    Koichiro Kudo
    BMC Infectious Diseases, 21
  • [38] Favipiravir, an antiviral for COVID-19?
    Coomes, Eric A.
    Haghbayan, Hourmazd
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2020, 75 (07) : 2013 - 2014
  • [39] Alectinib, COVID-19 and favipiravir
    Mungmunpuntipantip, Rujittika
    Wiwanitkit, Viroj
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2021, 27 (07) : 1810 - 1810
  • [40] Favipiravir for the treatment of patients with COVID-19: a systematic review and meta-analysis
    Manabe, Toshie
    Kambayashi, Dan
    Akatsu, Hiroyasu
    Kudo, Koichiro
    BMC INFECTIOUS DISEASES, 2021, 21 (01)
12345